Aiming to spur the immune responses that checkpoint inhibitors can't, Swiss biotech Numab earns fresh round of cash
Swiss antibody player Numab saw its last raise come in at just under $24 million, a Series B that closed in March 2020. But Thursday, the biotech brought in a whole new heaping of cash.
Numab secured a Series C of 100 million CHF, or roughly $110.6 million, to continue advancing its slate of multispecific offerings through preclinical and clinical studies. Its lead candidate, a trispecific that hits 4-1BB, PD-L1 and HSA, has entered its Phase I safety studies and Numab hopes to use Thursday’s funds to prep three Phase II cohorts for a proof-of-concept study sometime around the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
